ProQR Announces Strategic Changes to the Management Team and Key New Hires
December 13, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Global Diabetic Retinopathy Market Expected to Reach USD 9.3 Billion By 2024: Zion Market Research
December 06, 2018 07:10 ET
|
Zion Market Research
New York, NY, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Diabetic Retinopathy Market by Type (Non-Proliferative Diabetic Retinopathy and Proliferative...
Oxurion NV Business Update - Q3 2018
October 19, 2018 01:30 ET
|
Oxurion NV
Shareholders' Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular...
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
September 20, 2018 11:40 ET
|
Oxurion NV
Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in...
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
September 20, 2018 01:30 ET
|
Oxurion NV
Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company (formerly known as ThromboGenics) focused on developing treatments for back of the eye diseases with an...
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
September 17, 2018 11:40 ET
|
Oxurion NV
Leuven, Belgium, 17 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in...
Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit
September 10, 2018 01:30 ET
|
Oxurion NV
Oxurion NV trading under "OXUR" on NYSE Euronext Brussels Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation...
ThromboGenics Business Update - H1 2018
September 06, 2018 11:40 ET
|
Oxurion NV
Press release6 September 2018Regulated Information Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion NV €10 million equity...
ThromboGenics becomes "Oxurion"
September 03, 2018 11:40 ET
|
Oxurion NV
Press release Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders Leuven, Belgium, 3 September 2018 -...
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
July 19, 2018 11:40 ET
|
Oxurion NV
Press release Study results confirm safety and tolerability of THR-317 for intra-ocular use, and show improvement in visual acuity for up to 90 days after last injection Leuven, Belgium, 19 July...